Mark E. Saad Officer/Director Filing - Axsome Therapeutics, Inc.
2026-06-10SEC Filing 4 (0001193125-26-266436)
On June 8, 2026, Mark E. Saad, a director at Axsome Therapeutics, Inc., acquired 1,429 shares of Common Stock through a transaction coded "M" (